- Chembio Diagnostics Inc's CEMI Q2 sales increased 26% Y/Y to $6.5 million, missing the consensus of $8.5 million.
- Net product sales increased 4% to $3.9 million. Government grant, license, and royalty, and R&D revenue totaled $2.5 million, almost double from Q2 FY20.
- Chembio posted a wider operating loss of $8.3 million, compared to $7.3 million a year ago.
- R&D expenses increased 46% to $2.8 million, primarily associated with clinical and regulatory work related to pursuing a EUA and 510(k) from FDA for the DPP SARS-CoV-2 Antigen test system and a EUA for the DPP Respiratory Panel.
- EPS loss was $(0.45), wider than $(0.42) a year ago and missing the consensus of $(0.27).
- During the quarter, Chembio recognized $1.3 million of non-cash impairment loss from the write-off of the intangible assets and $0.7 million of restructuring costs related to professional fees.
- Cash and cash equivalents totaled $5.6 million.
- After Q2, $36.9 million of gross proceeds were raised through the ATM offering.
- Revenues during the June quarter did not meet the Company's expectations, and the shortfall in revenues was a principal cause of the Company's limited cash and cash equivalents position, according to the press release.
- It undertook measures to increase revenues and liquidity, with a $28.3 million purchase order from Bio-Manguinhos to purchase DPP SARS-CoV-2 Antigen tests for delivery during 2021 in Brazil.
- A $4 million purchase order from the Partnership for Supply Chain Management, supported by The Global Fund for its HIV 1/2 STAT-PAK Assay for shipment to Ethiopia into early 2022.
- Earlier this week, Chembio's partner LumiraDx's COVID-19 antibody test received an FDA emergency use nod.
- Price Action: CEMI shares are down 15.1% at $2.99 during the premarket session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
